ALS diagnosis
ALS research
ALS patients
new ALS drug
ALS diagnostic tool
ALS drug developer
final diagnosis of ALS
clinical development
ALS experimental therapeutic advancement
progression of clinical drug development
development time
Biomarker assay development
quick diagnostic assay
clinical trials
earlier diagnosis
Economic benefit
initial diagnosis
reliable diagnostic tool
practical diagnostic tests
benefit of potential therapeutic interventions
monitoring therapeutic efficacy
new therapies
new therapy
rare disease
unique Dutch SME Treeway
month delay
muscle spasticity
economic feasibility
similar symptoms
similar reasons
symptom onset
lack of accurate
EMA’s Orphan Medicinal Product Designation
progressive weakness
respiratory failure
combination
earth
paper study
assays
amyotrophic lateral sclerosis
face
field
Treeway’s mission
additional revenues
successful entrepreneurs
results
difficulties
walking
years
diseases
detectable biomarkers
market
availability
DEALS
developments